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Abstract
Background: Patients with fibrotic interstitial lung disease (ILD) are frequently physically inactive and many ILD
subtypes are characterized by risk factors for myopathy; however, the importance of body composition, muscle
strength, and physical performance in this population is largely unknown.
Methods: Patients were prospectively recruited from a specialized ILD clinic, baseline characteristics were collected
from the clinical record, pulmonary function tests were performed per established protocols, and dyspnea was
measured using the University of California San Diego Shortness of Breath Questionnaire. Dual-energy X-ray
absorptiometry (DXA) was used to assess body composition; handgrip strength to determine muscle strength, and
4-m gait speed to measure physical performance.
Results: One hundred and fifteen patients with fibrotic ILD including 40 patients with idiopathic pulmonary fibrosis
were recruited. The mean age was 69+/− 10 years in men (62% of the cohort), and 66+/− 9 years in women, with
mild and moderate reduction in FVC and DLCO, respectively, for both sexes. ILD severity (measured by FVC
%-predicted, DLCO %-predicted, or the Composite Physiologic Index in separate models) significantly predicted
muscle mass and percent body fat including with adjustment for age, sex, and weight. ILD severity was associated
with grip strength and gait speed independent from body composition.
Conclusions: ILD severity has an important impact on body composition, particularly in men. Future studies are
needed to confirm and further explore the possibility of additional pathways through which ILD directly impacts
limb muscle function and physical performance.
Keywords: Body composition, Exercise, physical, Lung diseases, Interstitial, Muscle strength, Respiratory function
tests
Introduction
Fibrotic interstitial lung diseases (ILDs) are progressive
disorders that have high morbidity and early mortality
[1, 2]. The morbidity of fibrotic ILD is primarily deter-
mined by disabling dyspnea and cough; however, extra-
pulmonary symptoms are also common (e.g., depression,
anxiety, fatigue) [3]. Together, these pulmonary and
extrapulmonary manifestations reduce physical activity
[4, 5], which in turn leads to limb muscle disuse and
deconditioning [6, 7]. The importance of limb muscle
dysfunction on quality of life, adverse health outcomes,
and mortality is well recognized in the general aging
population [8], and in patients with chronic obstructive
pulmonary disease (COPD) [9], but there are limited
data from patients with ILD.
Beyond the impact of muscle disuse and decondition-
ing, there are additional potential biological links be-
tween ILD and limb muscle dysfunction. For example,
many ILD subtypes are characterized by systemic in-
flammation, oxidative stress, hypoxemia, impaired en-
ergy balance, malnutrition, and accelerated biological
aging [10–12]. These are additional potential risk factors
for myopathy and limb muscle dysfunction that have
also not been adequately studied in fibrotic ILD [13–15].
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The overarching objective of this study was therefore to
explore the importance of body composition, muscle
strength, and physical performance in patients with fi-
brotic ILD. We hypothesized that ILD severity impacts
body composition independent of baseline demograph-
ics, and that ILD severity has a direct effect on limb
muscle function that is independent of muscle mass and
body fat.
Methods
Study population
Consecutive adult patients with idiopathic pulmonary fi-
brosis (IPF), idiopathic nonspecific interstitial pneumonia
(NSIP), chronic hypersensitivity pneumonitis (HP), and
unclassifiable ILD were prospectively invited to participate
from a specialized ILD clinic between January 2016 and
December 2017. Diagnoses were made using established
criteria where available or based on a multidisciplinary
discussion for ILDs without diagnostic criteria [16, 17].
Patients with ILD secondary to a systemic disease (e.g.,
connective tissue disease [CTD], sarcoidosis) and patients
with significant, active and/or uncontrolled cardiovascular,
musculoskeletal, metabolic, malignant, or neurological
disease that limited function or independence were
excluded.
Measurement of body composition, muscle function, and
physical performance
Dual-energy X-ray absorptiometry (DXA) was used to
assess body composition. This standard technique allows
precise, accurate, and reproducible differentiation be-
tween body fat mass, lean mass, and bone mineral con-
tent, with the possibility of obtaining regional measures
(e.g., upper or lower limb muscle mass) [18]. All DXA
scans were performed with a Hologic Discovery QDR
4500 (Hologic Inc., Bedford, MA). As recommended by
the European Working Group on Sarcopenia in Older
People [19], skeletal muscle index (SMI) was calculated
as the sum of the muscle mass of the upper and lower
limbs adjusted for height (m2). Percent body fat was cal-
culated as total fat mass divided by total body mass.
Limb muscle function was assessed by handgrip
strength [19], measured to the nearest kilogram using a
Baseline® HiRes™ hydraulic hand dynamometer. Patients
were seated with elbows flexed to 90 degrees and fore-
arms in neutral position, thumb facing upwards. Patients
were instructed to squeeze the dynamometer as hard as
possible alternating three times for each hand, with the
best measurement used for all analyses. Age-matched
reference values are available for the Canadian popula-
tion [20].
Physical performance was assessed with 4-m gait speed
(4MGS) [19], in which patients were instructed to walk
at their usual pace along a 4-m course as when walking
down a street. Canes and other walking aids were
allowed. The walk test was performed three times with
the fastest time used for all analyses. 4MGS has recently
been demonstrated as reliable, valid, and responsive to
change in patients with IPF [21].
Additional measurements
Demographics, baseline characteristics, and data on
prednisone use were collected from the clinical record,
with all measurements performed within 3 months of re-
cruitment. Pulmonary function tests were completed
using established protocols [22, 23]. Disease severity was
assessed using pulmonary physiology, including forced
vital capacity (FVC), diffusion capacity of the lung for
carbon monoxide (DLCO), and the Composite Physio-
logic Index (CPI), which was developed to predict radio-
logical severity of fibrosis by aggregating FVC, forced
expiratory volume in 1 s, and DLCO [24]. Dyspnoea was
measured using the University of California San Diego
Shortness of Breath Questionnaire (UCSD SOBQ), for
which patients rate their dyspnea severity during 21
common activities and indicate how much dyspnea
limits 3 aspects of their daily life, with each question
measured on a 0–5 scale (total range 0–120) [25].
Statistical analysis
Data are reported as mean (standard deviation) or median
(interquartile range). Variables were examined for normal-
ity with histograms. Transformation of variables was not
performed given the approximately normal distribution of
all variables included in multivariable linear models.
Between-group differences were analysed by chi2-test/
Fisher’s exact test for categorical variables and by
two-sample t-test/Wilcoxon rank-sum test for continuous
variables. Unadjusted associations between continuous
variables were determined by Pearson’s/Spearman’s correl-
ation test. Multivariable linear regression models were fit-
ted to examine the independent association of ILD
severity with body composition, limb muscle function,
and physical performance. The coefficient of determin-
ation (R2) was used to assess the percent of variance in
body composition, limb muscle function, and physical per-
formance that was explained by the linear model. Model
fit was compared by the Akaike Information Criterion
(AIC). A two-sided p < 0.05 was used to indicate statistical
significance for all comparisons. Data were analyzed using
R version 3.5.1 (R Foundation for Statistical Computing,
Vienna, Austria) [26].
Results
Patient characteristics
Of the 164 consecutive patients approached, 49 declined
participation and 71 men and 44 women consented to
participate, with a final study cohort of 115 patients. The
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most frequent diagnosis was IPF (34 men and 6 women),
followed by unclassifiable ILD (21 men and 16 women)
and chronic HP (10 men and 16 women), representing 35,
32, and 23% of the cohort, respectively, after excluding pa-
tients with CTD-ILD and other multisystem disorders.
The remaining 6 men and 6 women had cryptogenic or-
ganizing pneumonia (5), drug-induced ILD (3), vasculitis
(2), idiopathic NSIP (1), and idiopathic lymphocytic inter-
stitial pneumonia (1). On average, women were younger
and had smoked less than men, with both sexes having
mild reduction in FVC and moderately reduced DLCO on
average (Table 1). Patients with IPF were older and had
more severely impaired DLCO compared to patients with
non-IPF ILD (mean [SD] age 70 [7.7] versus 66 [10] years
and mean [SD] DLCO 46 [13] versus 53 [17] %-predicted,
respectively). IPF and non-IPF patients had no differences
in their body composition, limb muscle function, and
physical performance; all ILDs were therefore pooled for
all analyses.
Body composition, limb muscle function, and physical
performance
Men had higher SMI (7.9 kg/m2 versus 6.2 kg/m2), higher
muscle mass (total, upper limb, lower limb, and trunk),
higher bone mineral content, and stronger grip compared
to women (p < 0.001 for all comparisons). Women had
higher absolute and relative body fat than men (30 kg/40%
versus 25 kg/29%; p ≤ 0.006 for both comparisons). Gait
speed did not differ significantly between men and women
(1.33m/s versus 1.25m/s; Table 2).
Figure 1 shows the correlation among measures of
body composition, limb muscle function, and physical per-
formance in men and women. SMI was correlated with
age (r = − 0.40, p < 0.001) and weight (r = 0.69, p < 0.001)
in men and with weight (r = 0.71, p < 0.001) in women.
Percent body fat correlated with age (r = 0.24, p = 0.04)
and weight (r = 0.63, p < 0.001) in men and with weight
(r = 0.63, p < 0.001) in women. Grip strength correlated
with age (r = − 0.39, p < 0.001) and weight (r = 0.46,
p < 0.001) in men and with age (r = − 0.30, p = 0.047)
and weight (r = 0.33, p = 0.03) in women. Gait speed
was not associated with any baseline demographic or
anthropometric measurement in men or women.
Smoking history (smoked pack-years) and current or
previous use of prednisone were not associated with
SMI, percent body fat, grip strength, or gait speed,
and these variables were therefore not considered in
multivariable models.
Association of ILD severity with body composition
Several measures of ILD severity were associated with
body composition and particularly muscle mass. On un-
adjusted analysis, SMI was correlated with DLCO %-pre-
dicted and CPI in men but was not associated with any
measure of ILD severity in women (Table 3, Fig. 2a).
Greater ILD severity remained a significant predictor of
lower SMI in the full cohort with adjustment for age,
sex, and weight, regardless of whether ILD severity wasTable 1 Baseline characteristics
Men, n = 71 Women, n = 44
Demographics
Age, years 69 (10) 66 (9)
Height, cm 169 (9) 170 (8)
Weight, kg 79 (15) 82 (16)
Body mass index, kg/m2 28 (4) 28 (6)
Ever smoker 48 (68%) 25 (57%)
Smoked pack-years 23 (14–37) 10 (4–17)
ILD severity
FVC, %-predicted 77 (17) 72 (22)
DLCO, %-predicted 52 (16) 49 (17)
Dyspnea (UCSD SOBQ) 34 (22–54) 41 (23–58)
Composite Physiologic Index 45 (36–54) 48 (36–58)
Prednisone use
Current 7 (10%) 9 (21%)
Ever 12 (17%) 17 (39%)
Dose > 10mg daily 3 (4%) 1 (2%)
Data shown are mean (standard deviation), median (interquartile range), or
number (percent)
Abbreviations: DLCO diffusion capacity of the lung for carbon monoxide, FVC
forced vital capacity, ILD interstitial lung disease, UCSD SOBQ University of
California San Diego Shortness of Breath Questionnaire
Table 2 Body composition, limb muscle function and physical
performance
Men, n = 71 Women, n = 44 p-value*
Mean (SD) Mean (SD)
Body composition
SMI, kg/m2 7.9 (0.9) 6.2 (1.0) < 0.0001
ALM, kg 24.0 (3.7) 16.2 (2.6) < 0.0001
Upper limb, kg 6.2 (1.2) 3.6 (6.5) < 0.0001
Lower limb, kg 17.8 (2.7) 12.6 (2.2) < 0.0001
Trunk, kg 32.6 (5.0) 25.2 (4.1) < 0.0001
Body fat, kg 25.1 (7.8) 29.7 (9.1) 0.006
Body fat, % 29.1 (5.2) 39.8 (6.5) < 0.0001
Total BMC, kg 2.8 (0.6) 2.1 (0.4) < 0.0001
Limb muscle function
Dominant hand, kg 40.2 (9.6) 25.6 (5.7) < 0.0001
Non-dominant hand, kg 37.5 (9.3) 24.2 (6.4) < 0.0001
Physical performance
4-m gait speed, m/s 1.33 (0.3) 1.25 (0.3) 0.16
Abbreviations: ALM appendicular lean mass, BMC bone mineral content, SMI
skeletal muscle index
*Two sample t-test
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represented by FVC %-predicted, DLCO %-predicted, or
the CPI. The multivariable models explained 75–76% of
the variability in SMI (Table 3). On unadjusted analysis,
percent body fat correlated with FVC %-predicted and
dyspnea in men and with FVC %-predicted in women
(Table 3, Fig. 2b). Lower FVC %-predicted was the only
ILD severity measure that was independently associated
with higher percent body fat with adjustment for age,
sex, and weight on adjusted analysis (Table 3).
Association of ILD severity with limb muscle function and
physical performance
Measures of ILD severity were associated with grip
strength and gait speed independent of body compos-
ition. On unadjusted analysis, grip strength correlated
with CPI in men, but was not associated with any meas-
ure of ILD severity in women (Table 4, Fig. 3a). DLCO
%-predicted, CPI, and dyspnea were independent predic-
tors of grip strength in separate models that each
Fig. 1 Pairwise correlation of body composition, limb muscle function, and physical performance. Abbreviations: SMI, skeletal muscle index (kg/
m2), UL muscle, upper limb muscle mass (kg); LL muscle, lower limb muscle mass (kg); % Bodyfat, percent of fat mass/total body mass (%), Grip
strength, handgrip strength (kg); Gait speed, 4-m gait speed (m/s); r, Pearson’s correlation coefficient
Table 3 Unadjusted and adjusted correlation of ILD severity with body composition
Unadjusted analysis Adjusted for sex, age, weight
Men Women
r p-value r p-value Coefficient (95% CI) p-value R2
SMI, kg/m2
FVC, %-predicted 0.22 0.07 −0.06 0.71 0.012 (0.005 to 0.018) 0.0006 0.75
DLCO, %-predicted 0.39 0.002 0.15 0.40 0.013 (0.006 to 0.021) 0.0009 0.76
CPI −0.40 0.002 −0.19 0.27 −0.016 (− 0.026 to − 0.007) 0.0001 0.76
Dyspnea (UCSD SOBQ) − 0.08 0.57 0.29 0.09 −0.004 (− 0.010 to 0.002) 0.19 0.74
Body fat, %
FVC, %-predicted −0.37 0.002 −0.30 0.04 −0.063 (− 0.105 to − 0.020) 0.004 0.70
DLCO, %-predicted 0.03 0.79 0.12 0.51 0.001 (−0.050 to 0.052) 0.96 0.68
CPI 0.05 0.68 −0.06 0.74 0.025 (−0.036 to 0.087) 0.42 0.69
Dyspnea (UCSD SOBQ) 0.41 0.003 0.28 0.09 0.021 (−0.017 to 0.060) 0.28 0.70
Coefficients are reported per one-unit change for the predictor variables. A positive coefficient indicates an increase in the outcome variable per unit of the
predictor variable (e.g., SMI increases by an average of 0.012 kg/m2 for every 1% increase of FVC %-predicted)
Abbreviations: CI confidence interval, CPI Composite Physiologic Index, C diffusion capacity of the lung for carbon monoxide, FVC forced vital capacity, r Pearson’s
correlation coefficient, R2 coefficient of determination (variability in the outcome explained by the model), SMI skeletal muscle index, UCSD SOBQ University of
California San Diego Shortness of Breath Questionnaire
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adjusted for age, sex, weight, and body composition. On
unadjusted analysis, gait speed correlated with FVC
%-predicted, DLCO %-predicted, CPI, and dyspnea in
men and with dyspnea in women (Table 4, Fig. 3b). Gait
speed was correlated with all measures of ILD severity
with adjustment for baseline confounders and body
composition. The models explained a greater percentage
of the variability in grip strength (R2 0.65–0.68) than in
gait speed (R2 0.07–0.16; Table 4).
Discussion
In this prospective cohort study, we show that ILD se-
verity is strongly associated with body composition in
both men and women, with significantly lower muscle
mass and higher fat mass in individuals with more
impaired pulmonary function. We also show that ILD
severity is associated with upper limb muscle dysfunc-
tion and worse physical performance independent of
muscle mass or body fat percentage. The independent
ba
Fig. 2 Correlation of ILD severity with body composition (a, skeletal muscle mass; b, percent body fat) in men and women with fibrotic ILD.
Abbreviation: r, Pearson’s correlation coefficient
Table 4 Unadjusted and adjusted correlation of ILD severity with physical performance
Unadjusted analysis Adjusted for sex, age, weight, SMI, % body fat
Men Women
r p-value r p-value Coefficient (95% CI) p-value R2
Grip strength, kg
FVC, %-predicted 0.17 0.16 − 0.13 0.41 0.050 (− 0.022 to 0.122) 0.17 0.65
DLCO, %-predicted 0.16 0.21 0.22 0.20 0.115 (0.026 to 0.204) 0.01 0.67
CPI −0.29 0.03 − 0.31 0.08 − 0.140 (− 0.247 to − 0.034) 0.01 0.66
Dyspnea (UCSD SOBQ) −0.08 0.58 −0.07 0.71 −0.066 (− 0.122 to − 0.010) 0.02 0.68
Gait speed, m/s
FVC, %-predicted 0.35 0.003 0.16 0.30 0.004 (0.001 to 0.007) 0.01 0.10
DLCO, %-predicted 0.25 0.049 0.06 0.71 0.004 (0.0005 to 0.008) 0.03 0.07
CPI −0.29 0.02 −0.06 0.72 −0.006 (− 0.011 to − 0.002) 0.009 0.08
Dyspnea (UCSD SOBQ) − 0.28 0.04 − 0.49 0.003 − 0.005 (− 0.007 to − 0.002) 0.0003 0.16
Coefficients are reported per one-unit change for the predictor variables. A positive coefficient indicates an increase in the outcome variable per unit of the
predictor variable (e.g., grip strength increases by an average of 0.115 kg for every 1% increase of DLCO %-predicted)
Abbreviations: CI confidence interval, CPI composite physiologic index, DLCO diffusion capacity of the lung for carbon monoxide, FVC forced vital capacity, r
Pearson’s correlation coefficient, R2 coefficient of determination (variability in the outcome explained by the model), SMI skeletal muscle index, UCSD SOBQ
University of California San Diego Shortness of Breath Questionnaire
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association of ILD severity with physical performance in-
dicates that ILD severity has an important impact on
measures of physical deconditioning in fibrotic ILD and
suggests the possibility of additional pathways through
which ILD directly impacts limb muscle function and
physical performance. This novel finding was observed
using multiple measures of ILD severity, was independ-
ent of baseline characteristics, and was not explained by
the use of prednisone.
Our ILD patients had lower muscle mass and body fat
percentage compared to previously published commu-
nity dwelling older adults [27]. Men with fibrotic ILD
also had substantially weaker grip strength compared to
an age-matched healthy Canadian population, although
grip strength was not lower than expected in women
with fibrotic ILD [20]. These findings highlight the need
for additional study of muscle mass and function in pa-
tients with fibrotic ILD. In contrast, 4MGS in our cohort
was similar to the general population and markedly fas-
ter than a recently reported IPF population in the UK
[21, 28]. The 4MGS is a simple, reliable, and responsive
measurement for assessing global physical performance
and functionality in COPD [29]; however, it was only
weakly correlated with body composition in our cohort
and only 10% of the variability in 4MGS was explained
by ILD severity, age, sex, height, and body composition.
This reflects an important contribution of unmeasured
factors to 4MGS, and potentially poor construct validity
of this test in our cohort.
There are two primary mechanisms by which ILD may
lead to changes in muscle mass and function. First, ILD
frequently leads to inactivity, muscle disuse, and
deconditioning as patients attempt to avoid the uncom-
fortable symptom of exertional dyspnea. Second, patients
with ILD frequently have risk factors for myopathy in-
cluding alterations in sex and growth hormones. The
impact of sex and growth hormones on muscle mass
and function is well established in the general popula-
tion [30, 31], and studies in COPD suggest a role of tes-
tosterone, other anabolic steroids, and myostatin in the
development of age- and disease-related muscle wasting
[32–34]. Similarly, patients with IPF have lower levels of
the steroid hormone dehydroepiandrosterone (DHEA)
[35], potentially explaining the more consistent and
stronger association of ILD severity with unfavourable
body composition and low physical function in men
compared to women. Furthermore, DHEA has antifibro-
tic effects on in vitro human fibroblasts [35], indicating
the need for future studies to explore the links between
hormones, limb muscles, and disease progression in pa-
tients with fibrotic ILD.
Weight loss is a strong negative prognostic factor in
patients with COPD [36, 37]; however, the prognostic
importance of low body mass in patients with fibrotic
ILD is more controversial [10, 38, 39]. Recent studies
showed that erector spinae cross-sectional-muscle-area
and fat free mass might be prognostically important for
patients with IPF [39, 40], but neither body mass index
nor body composition correlated with measures of dis-
ease severity [39]. Our novel detection of the correlation
of ILD severity with body composition might be due to
our larger sample size and our use of DXA to measure
body composition, which is more precise at an individual
patient level than bioelectrical impedance analysis that
ba
Fig. 3 Correlation of ILD severity with limb muscle function (a) and physical performance (b) in men and women with fibrotic ILD. Abbreviation:
r, Pearson’s correlation coefficient
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was used in the previous study [39, 41]. The prognostic
significance of handgrip strength and 4MGS [21] in fi-
brotic ILD still needs to be determined. Studies in
COPD suggest that body composition [42], muscle
strength and physical performance [42–44] might be
predictors of morbidity and mortality in respiratory dis-
eases, emphasizing the potential importance of specific-
ally targeting loss of muscle mass and limb muscle
dysfunction in patients with fibrotic ILD.
Our findings have potential implications for the de-
sign of exercise training programs for patients with
ILD, which can improve physical performance and re-
duce muscle fatigue [21, 45]. The lower muscle mass in
our cohort compared to community dwelling older
adults and its association with ILD severity suggest that
individualized exercise programs for these patients
should employ physical training strategies aimed to
prevent and treat loss of muscle mass, which may
further improve muscle performance. For example, se-
quential high intensity training of fewer muscle groups
and neuromuscular stimulation may provide a suffi-
ciently intense stimulus that can lead to muscle adapta-
tion prior to the onset of limiting dyspnea in patients
with severe ILD [46, 47]. Non-exercise strategies to pre-
vent and treat limb muscle dysfunction have been eval-
uated in COPD [48], including nutritional support,
oxygen therapy, and management of comorbidities.
Such strategies should similarly be evaluated in the
management of body composition and physical per-
formance in patients with fibrotic ILD.
This cross-sectional study design allows only specu-
lation about causality of the associations between ILD
severity, body composition, limb muscle function, and
physical performance. It is plausible that more ad-
vanced ILD leads to muscle disuse and myopathy, but
common unidentified mechanisms causing myopathy
and lung fibrosis can’t be excluded. Similarly, this co-
hort study is not able to clarify the biological mecha-
nisms of abnormal body composition and physical
performance in patients with fibrotic ILD. Finally, in-
stead of having a direct control group, we compared
body composition and physical performance measures
to previously reported general populations and COPD
cohorts.
Conclusions
Maintaining independence in the growing elderly ILD
population will become increasingly important in the
future, particularly considering advances in ILD
pharmacotherapy that might prolong survival. The de-
velopment of management strategies counteracting the
detrimental loss of muscle mass and function in pa-
tients with fibrotic ILD requires a deeper understanding
of their physiologic basis. In this study we demonstrate
a significant impact of ILD severity and dyspnea on
body composition, muscle strength, and physical per-
formance. Future studies in patients with fibrotic ILD
are needed to investigate the impact of reduced muscle
mass and physical function on long-term clinical out-
comes, to identify potential management strategies, and
to explore the underlying biological basis for these
sex-dependent associations.
Abbreviations
4MGS: 4-m gait speed; ALM: Appendicular lean mass; BMC: Bone mineral
content; CI: Confidence interval; COPD: Chronic obstructive pulmonary
disease; CPI: Composite Physiologic Index; CTD: Connective tissue disease;
DLCO: Diffusion capacity of the lung for carbon monoxide; DXA: Dual-energy
X-ray absorptiometry; FVC: Forced vital capacity; HP: Hypersensitivity
pneumonitis; ILD: Interstitial lung disease; IPF: Idiopathic pulmonary fibrosis;
NSIP: Nonspecific interstitial pneumonia; SMI: Skeletal muscle index; UCSD
SOBQ: University of California San Diego Shortness of Breath Questionnaire
Acknowledgments
The authors would like to acknowledge the patients of the St. Paul’s Hospital
ILD Clinic who allow us to conduct this research in an effort to improve the
lives of patients with ILD.
Funding
This work was supported by the British Columbia Lung Association and the
Canadian Pulmonary Fibrosis Foundation.
Availability of data and materials
The datasets used and analysed during the current study are available from
the corresponding author on reasonable request.
Authors’ contributions
CJR takes responsibility for the content of the manuscript, including the data
and analysis and is guarantor of this paper. SAG and CJR contributed to the
conception and design of the study, and acquisition, analysis, and
interpretation of the data. SAH, SAL, and PGC contributed to the acquisition
of the data. All authors revised the manuscript for important intellectual
content and provided final approval of the version to be published.
Ethics approval and consent to participate
All participants provided written informed consent for participation in the
current study (University of British Columbia ethics board approval H15–
02350).
Competing interests
The authors (SAG, SAH, SAL, PGC, and CJR) declare that they have no
competing interests relevant to this work.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Medicine, University of British Columbia, Vancouver, Canada.
2Centre for Heart Lung Innovation, University of British Columbia, Vancouver,
Canada. 3Department of Pulmonary Medicine, University Hospital and
University of Bern, Bern, Switzerland. 4Faculty of Health Sciences, Simon
Fraser University, Burnaby, Canada. 5Department of Physical Therapy,
University of British Columbia, Vancouver, Canada. 6St. Paul’s Hospital, 1081
Burrard St, Ward 8B, Vancouver, BC V6Z 1Y6, Canada.
Guler et al. Respiratory Research           (2019) 20:56 Page 7 of 9
Received: 31 October 2018 Accepted: 27 February 2019
References
1. Marshall DC, Salciccioli JD, Shea BS, Akuthota P. Trends in mortality from
idiopathic pulmonary fibrosis in the European Union: an observational study
of the WHO mortality database from 2001-2013. Eur Respir J. 2018;51(1).
2. Navaratnam V, Fogarty AW, Glendening R, McKeever T, Hubbard RB. The
increasing secondary care burden of idiopathic pulmonary fibrosis: hospital
admission trends in England from 1998 to 2010. Chest. 143(4):1078–84.
3. Glaspole IN, Watson AL, Allan H, Chapman S, Cooper WA, Corte TJ, Ellis S,
Grainge C, Goh N, Hopkins P, Keir G, Macansh S, Mahar A, Moodley Y,
Reynolds PN, Ryerson CJ, Walters EH, Zappala CJ, Holland AE. Determinants
and outcomes of prolonged anxiety and depression in idiopathic
pulmonary fibrosis. Eur Respir J. 2017;50(2).
4. Root ED, Graney B, Baird S, Churney T, Fier K, Korn M, McCormic M,
Sprunger D, Vierzba T, Wamboldt FS, Swigris JJ. Physical activity and activity
space in patients with pulmonary fibrosis not prescribed supplemental
oxygen. BMC Pulm Med. 2017;17(1):154.
5. Nishiyama O, Yamazaki R, Sano H, Iwanaga T, Higashimoto Y, Kume H,
Tohda Y. Physical activity in daily life in patients with idiopathic pulmonary
fibrosis. Respir Investig. 2018;56(1):57–63.
6. Jones SE, Maddocks M, Kon SS, Canavan JL, Nolan CM, Clark AL, Polkey MI,
Man WD. Sarcopenia in COPD: prevalence, clinical correlates and response
to pulmonary rehabilitation. Thorax. 2015;70(3):213–8.
7. Morino A, Takahashi H, Chiba H, Ishiai S. Daily physical activity affects
exercise capacity in patients with idiopathic pulmonary fibrosis. J Phys Ther
Sci. 2017;29(8):1323–8.
8. Leong DP, Teo KK, Rangarajan S, Lopez-Jaramillo P, Avezum A Jr, Orlandini
A, Seron P, Ahmed SH, Rosengren A, Kelishadi R, Rahman O, Swaminathan
S, Iqbal R, Gupta R, Lear SA, Oguz A, Yusoff K, Zatonska K, Chifamba J,
Igumbor E, Mohan V, Anjana RM, Gu H, Li W, Yusuf S. Prognostic value of
grip strength: findings from the prospective urban rural epidemiology
(PURE) study. Lancet. 2015;386(9990):266–73.
9. Burtin C, Ter Riet G, Puhan MA, Waschki B, Garcia-Aymerich J, Pinto-Plata V,
Celli B, Watz H, Spruit MA. Handgrip weakness and mortality risk in COPD: a
multicentre analysis. Thorax. 2016;71(1):86–7.
10. Alakhras M, Decker PA, Nadrous HF, Collazo-Clavell M, Ryu JH. Body mass
index and mortality in patients with idiopathic pulmonary fibrosis. Chest.
2007;131(5):1448–53.
11. Rahman I, Skwarska E, Henry M, Davis M, O’Connor CM, FitzGerald MX,
Greening A, MacNee W. Systemic and pulmonary oxidative stress in
idiopathic pulmonary fibrosis. Free Radic Biol Med. 1999;27(1–2):60–8.
12. Snetselaar R, van Moorsel CH, Kazemier KM, van der Vis JJ, Zanen P, van
Oosterhout MF, Grutters JC. Telomere length in interstitial lung diseases.
Chest. 2015;148(4):1011–8.
13. Schaap LA, Pluijm SM, Deeg DJ, Visser M. Inflammatory markers and loss of
muscle mass (sarcopenia) and strength. Am J Med. 2006;119(6):526.e529–17.
14. Hoppeler H, Kleinert E, Schlegel C, Claassen H, Howald H, Kayar SR, Cerretelli
P. Morphological adaptations of human skeletal muscle to chronic hypoxia.
Int J Sports Med. 1990;11(Suppl 1):S3–9.
15. Meyer A, Salewsky B, Spira D, Steinhagen-Thiessen E, Norman K, Demuth I.
Leukocyte telomere length is related to appendicular lean mass: cross-
sectional data from the Berlin aging study II (BASE-II). Am J Clin Nutr. 2016;
103(1):178–83.
16. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV,
Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU,
Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh
T, Kim DS, King TE, Jr., Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi
L, Selman M, Dudden RF, Griss BS, Protzko SL, Schunemann HJ: An official
ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based
guidelines for diagnosis and management. Am J Respir Crit Care Med 2011,
183(6):788–824.
17. Travis WD, Costabel U, Hansell DM, King TE, Jr., Lynch DA, Nicholson AG,
Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby
TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan
J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J,
Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J,
Valeyre D, Pneumonias AECoII: An official American Thoracic Society/
European Respiratory Society statement: update of the international
multidisciplinary classification of the idiopathic interstitial pneumonias. Am J
Respir Crit Care Med, 188(6):733–748.
18. Lukaski HC, Marchello MJ, Hall CB, Schafer DM, Siders WA. Soft tissue
composition of pigs measured with dual x-ray absorptiometry: comparison
with chemical analyses and effects of carcass thicknesses. Nutrition. 1999;
15(9):697–703.
19. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F,
Martin FC, Michel JP, Rolland Y, Schneider SM, Topinkova E,
Vandewoude M, Zamboni M. European working group on sarcopenia in
older P: sarcopenia: European consensus on definition and diagnosis:
report of the European working group on sarcopenia in older people.
Age Ageing. 2010;39(4):412–23.
20. Wong SL. Grip strength reference values for Canadians aged 6 to 79: Canadian
health measures survey, 2007 to 2013. Health Reports. 2016;27(10):3–10.
21. Nolan CM, Maddocks M, Maher TM, Canavan JL, Jones SE, Barker RE, Patel S,
Jacob J, Cullinan P, Man WD. Phenotypic characteristics associated with
slow gait speed in idiopathic pulmonary fibrosis. Respirology. 2017.
22. Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco
V, Burgos F, Casaburi R, Coates A, Enright P, Gustafsson P, Hankinson J,
Jensen R, McKay R, Miller MR, Navajas D, Pedersen OF, Pellegrino R, Wanger
J. Standardisation of the single-breath determination of carbon monoxide
uptake in the lung. Eur Respir J. 2005;26(4):720–35.
23. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R,
Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC,
MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G,
Wanger J. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–38.
24. Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG, Colby TV,
du Bois RM, Hansell DM. Idiopathic pulmonary fibrosis: a composite
physiologic index derived from disease extent observed by computed
tomography. Am J Respir Crit Care Med. 2003;167(7):962–9.
25. Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM. Validation of a new
dyspnea measure: the UCSD shortness of breath questionnaire. University of
California, San Diego. Chest. 1998;113(3):619–24.
26. Team RC. R: a language and environment for statistical computing. Vienna:
R Foundation for Statistical Computing; 2016.
27. Kelly TL, Wilson KE, Heymsfield SB. Dual energy X-ray absorptiometry body
composition reference values from NHANES. PLoS One. 2009;4(9):e7038.
28. Newman AB, Kupelian V, Visser M, Simonsick E, Goodpaster B, Nevitt M,
Kritchevsky SB, Tylavsky FA, Rubin SM, Harris TB. Sarcopenia: alternative
definitions and associations with lower extremity function. J Am Geriatr Soc.
2003;51(11):1602–9.
29. Kon SS, Canavan JL, Nolan CM, Clark AL, Jones SE, Cullinan P, Polkey MI,
Man WD. The 4-metre gait speed in COPD: responsiveness and minimal
clinically important difference. Eur Respir J. 2014;43(5):1298–305.
30. Guadalupe-Grau A, Carnicero JA, Losa-Reyna J, Tresguerres J, Gomez-Cabrera
MD, Castillo C, Alfaro-Acha A, Rosado-Artalejo C, Rodriguez-Manas L, Garcia-
Garcia FJ. Endocrinology of aging from a muscle function point of view: results
from the Toledo study for healthy aging. J Am Med Dir Assoc. 2016.
31. Valenti G, Denti L, Maggio M, Ceda G, Volpato S, Bandinelli S, Ceresini G,
Cappola A, Guralnik JM, Ferrucci L. Effect of DHEAS on skeletal muscle over the
life span: the InCHIANTI study. J Gerontol A Biol Sci Med Sci. 2004;59(5):466–72.
32. Ju CR, Chen RC. Serum myostatin levels and skeletal muscle wasting in
chronic obstructive pulmonary disease. Respir Med. 2012;106(1):102–8.
33. Creutzberg EC, Wouters EF, Mostert R, Pluymers RJ, Schols AM. A role for
anabolic steroids in the rehabilitation of patients with COPD? A double-
blind, placebo-controlled, randomized trial. Chest. 2003;124(5):1733–42.
34. Casaburi R, Bhasin S, Cosentino L, Porszasz J, Somfay A, Lewis MI, Fournier
M, Storer TW. Effects of testosterone and resistance training in men with
chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;
170(8):870–8.
35. Mendoza-Milla C, Valero Jimenez A, Rangel C, Lozano A, Morales V, Becerril
C, Chavira R, Ruiz V, Barrera L, Montano M, Pardo A, Selman M.
Dehydroepiandrosterone has strong antifibrotic effects and is decreased in
idiopathic pulmonary fibrosis. Eur Respir J. 2013;42(5):1309–21.
36. Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of
nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit
Care Med. 1999;160(6):1856–61.
37. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA,
Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea,
and exercise capacity index in chronic obstructive pulmonary disease. N
Engl J Med. 2004;350(10):1005–12.
Guler et al. Respiratory Research           (2019) 20:56 Page 8 of 9
38. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V,
Buccioli M, Elicker BM, Jones KD, King TE Jr, Collard HR. A multidimensional
index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med.
2012;156(10):684–91.
39. Nishiyama O, Yamazaki R, Sano H, Iwanaga T, Higashimoto Y, Kume H,
Tohda Y. Fat-free mass index predicts survival in patients with idiopathic
pulmonary fibrosis. Respirology. 2016.
40. Suzuki Y, Yoshimura K, Enomoto Y, Yasui H, Hozumi H, Karayama M,
Furuhashi K, Enomoto N, Fujisawa T, Nakamura Y, Inui N, Suda T. Distinct
profile and prognostic impact of body composition changes in idiopathic
pulmonary fibrosis and idiopathic pleuroparenchymal fibroelastosis. Sci Rep.
2018;8(1):14074.
41. Buckinx F, Reginster JY, Dardenne N, Croisiser JL, Kaux JF, Beaudart C,
Slomian J, Bruyere O. Concordance between muscle mass assessed by
bioelectrical impedance analysis and by dual energy X-ray absorptiometry: a
cross-sectional study. BMC Musculoskelet Disord. 2015;16:60.
42. Schols AM, Broekhuizen R, Weling-Scheepers CA, Wouters EF. Body
composition and mortality in chronic obstructive pulmonary disease. Am J
Clin Nutr. 2005;82(1):53–9.
43. Puhan MA, Siebeling L, Zoller M, Muggensturm P, ter Riet G. Simple
functional performance tests and mortality in COPD. Eur Respir J. 2013;
42(4):956–63.
44. Martinez CH, Diaz AA, Meldrum CA, McDonald MN, Murray S, Kinney
GL, Hokanson JE, Curtis JL, Bowler RP, Han MK, Washko GR, Regan EA.
Handgrip strength in chronic obstructive pulmonary disease.
Associations with acute exacerbations and body composition. Ann Am
Thorac Soc. 2017;14(11):1638–45.
45. Tonelli R, Cocconcelli E, Lanini B, Romagnoli I, Florini F, Castaniere I,
Andrisani D, Cerri S, Luppi F, Fantini R, Marchioni A, Beghe B, Gigliotti F,
Clini EM. Effectiveness of pulmonary rehabilitation in patients with
interstitial lung disease of different etiology: a multicenter prospective
study. BMC Pulm Med. 2017;17(1):130.
46. Dolmage TE, Goldstein RS. Effects of one-legged exercise training of
patients with COPD. Chest. 2008;133(2):370–6.
47. Maddocks M, Nolan CM, Man WD, Polkey MI, Hart N, Gao W, Rafferty GF,
Moxham J, Higginson IJ. Neuromuscular electrical stimulation to improve
exercise capacity in patients with severe COPD: a randomised double-blind,
placebo-controlled trial. Lancet Respir Med. 2016;4(1):27–36.
48. Maltais F, Decramer M, Casaburi R, Barreiro E, Burelle Y, Debigare R,
Dekhuijzen PN, Franssen F, Gayan-Ramirez G, Gea J, Gosker HR, Gosselink R,
Hayot M, Hussain SN, Janssens W, Polkey MI, Roca J, Saey D, Schols AM,
Spruit MA, Steiner M, Taivassalo T, Troosters T, Vogiatzis I, Wagner PD. An
official American Thoracic Society/European Respiratory Society statement:
update on limb muscle dysfunction in chronic obstructive pulmonary
disease. Am J Respir Crit Care Med. 2014;189(9):e15–62.
Guler et al. Respiratory Research           (2019) 20:56 Page 9 of 9
